Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent is associated with lower risk for Alzheimer's disease (AD) in patients with rheumatoid arthritis (RA), psoriasis, and other inflammatory diseases which are mediated in part by TNF and for which a TNF blocker is an approved treatment. The analysis compared the diagnosis of AD as an outcome measure in patients receiving at least one prescription for a TNF blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate. Adjusted odds ratios (AORs) were estimated using the Cochran-Mantel-Haenszel (CMH) method and presented with 95% confidence intervals (CIs) and p-values. RA was associated with a higher risk for AD (Adjusted Odds Ratio (AOR) = 2.06, 95% Confidence Interval: (2.02-2.10), P-value <0.0001) as did psoriasis (AOR = 1.37 (1.31-1.42), P <0.0001), ankylosing spondylitis (AOR = 1.57 (1.39-1.77), P <0.0001), inflammatory bowel disease (AOR = 2.46 (2.33-2.59), P < 0.0001), ulcerative colitis (AOR = 1.82 (1.74-1.91), P <0.0001), and Crohn's disease (AOR = 2.33 (2.22-2.43), P <0.0001). The risk for AD in patients with RA was lower among patients treated with etanercept (AOR = 0.34 (0.25-0.47), P <0.0001), adalimumab (AOR = 0.28 (0.19-0.39), P < 0.0001), or infliximab (AOR = 0.52 (0.39-0.69), P <0.0001). Methotrexate was also associated with a lower risk for AD (AOR = 0.64 (0.61-0.68), P <0.0001), while lower risk was found in patients with a prescription history for both a TNF blocker and methotrexate. Etanercept and adalimumab also were associated with lower risk for AD in patients with psoriasis: AOR = 0.47 (0.30-0.73 and 0.41 (0.20-0.76), respectively. There was no effect of gender or race, while younger patients showed greater benefit from a TNF blocker than did older patients. This study identifies a subset of patients in whom systemic inflammation contributes to risk for AD through a pathological mechanism involving TNF and who therefore may benefit from treatment with a TNF blocking agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have demonstrated that a proinflammatory state (148–150), inflammatory disease (e.g., rheumatoid arthritis) (151), and immune challenges (e.g., acute infection) (152, 153) all increase the risk for dementia over multiple decades.”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [151]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“TLR4 encodes the Toll like receptor 4, a receptor in microglia, monocytes and macrophages that triggers TNF release when activated by lipopolysaccharide, or in the case of microglia, by amyloid beta peptide [41].”
BackgroundFate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175 · cited 1×
“Microglia cells, the resident macrophages in the brain, derive embryonically from the same myeloid stem cells in bone marrow that give rise to monocytes and macrophages elsewhere in the body [4].”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Diagnosis and Management of Rheumatoid Arthritis: A Review
Aletaha, D., & Smolen, J. S. (2018) · JAMA · doi:10.1001/jama.2018.13103 · Cited by 2,313
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Even with carefully selected patients enrolled in large, multi-center, Phase 3 clinical trials, AD is misdiagnosed based solely on clinical criteria in up to 25% of patients [35, 36].”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 1×
“Neuroinflammatory changes around the amyloid plaques include reactive astrocytosis and microglial cell activation [3].”
BackgroundMicroglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767 · cited 1×
“Microglia activation and gliosis formerly were considered secondary to neurodegeneration in AD, however, recent genetic studies in late-onset AD implicate microglia- and astrocyterelated pathways in disease pathogenesis.[10, 48, 49] One focus of interest is TREM2, an innate immune receptor expressed on microglia and m…”
ResultPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“Even with carefully selected patients enrolled in large, multi-center, Phase 3 clinical trials, AD is misdiagnosed based solely on clinical criteria in up to 25% of patients [35, 36].”
BackgroundTransgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.
Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., & Kollias, G. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04978.x · Cited by 1,660 · cited 1×
“Inflammation in RA is localized to the synovial lining of the joints where synovial cell proliferation leads to a thickening of the lining, infiltration of activated macrophages and other inflammatory cells, elevated production of TNF, and irreversible destruction of the joint architecture and function [11].”
BackgroundBaumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660
Klareskog, L., Stolt, P., Lundberg, K., Källberg, H., Bengtsson, C., Grunewald, J., Rönnelid, J., Erlandsson Harris, H., Ulfgren, A., Rantapää‐Dahlqvist, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21575 · Cited by 1,515
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069 · cited 1×
“A previous study of Parkinson’s disease in patients with co-morbid inflammatory bowel disease reported that TNF blocking agents were associated with decreased incidence of Parkinson’s disease[43], while therapeutic benefit was reported earlier for reducing risk of major depression in a pivotal, Phase 3 clinical trial…”
BackgroundARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,012 · cited 1×
“[10, 48, 49] One focus of interest is TREM2, an innate immune receptor expressed on microglia and myeloid cells [50, 51].”
BackgroundAl-Atrache, Z., Cader, A., & Appelt, D. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.894 · Cited by 765
Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders
Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.013 · Cited by 718
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, M. A., Vilcek, J., Daddona, P., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 703 · cited 1×
“Adalimumab (Humira1) is a fully human, anti-TNF monoclonal antibody [18], while infliximab (Remicade1) is a chimeric mouse-human monoclonal antibody in which the antigen combining region of a mouse anti-TNF monoclonal antibody is fused to a human Fc domain [19].”
BackgroundSugiyama, D., Nishimura, K., Tamaki, K., Tsuji, G., Nakazawa, T., Morinobu, A., & Kumagai, S. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096487 · Cited by 667
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535 · cited 1×
“Epidemiologic studies previously suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk for AD [59].”
BackgroundIntrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 1×
“In the brain, elevation of TNF in cerebrospinal fluid collected from subjects with mild cognitive impairment is associated with progression to AD at 6 months follow up [6].”
BackgroundTNF and its receptors in the CNS: The essential, the desirable and the deleterious effects
Probert, L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.038 · Cited by 495 · cited 1×
“NFKBIA and NFKBIZ are components of the nuclear I kappa B protein signaling pathway that regulates the expression of TNF while TNFSR1A encodes the TNF receptor superfamily member 1A that is activated by TNF [47].”
BackgroundA randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Normalized names for clinical drugs: RxNorm at 6 years
Nelson, S. J., Zeng, K., Kilbourne, J., Powell, T., & Moore, R. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000116 · Cited by 453 · cited 2×
“The Explorys Cohort Discovery platform has standardized all drug names to their generic names based on RxNorm.”
MethodTREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440 · cited 2×
“[10, 48, 49] One focus of interest is TREM2, an innate immune receptor expressed on microglia and myeloid cells [50, 51].”
BackgroundPeter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386
Do glia drive synaptic and cognitive impairment in disease?
Chung, W.-S., Welsh, C. A., Barres, B. A., & Stevens, B. (2015) · Nature Neuroscience · doi:10.1038/nn.4142 · Cited by 385 · cited 1×
“Microglia activation and gliosis formerly were considered secondary to neurodegeneration in AD, however, recent genetic studies in late-onset AD implicate microglia- and astrocyterelated pathways in disease pathogenesis.[10, 48, 49] One focus of interest is TREM2, an innate immune receptor expressed on microglia and m…”
ResultRofecoxib: No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study
Reines, S. A., Block, G. A., Morris, J. C., Liu, G., Nessly, M. L., Lines, C. R., Norman, B. A., & Baranak, C. C. (2004) · Neurology · doi:10.1212/wnl.62.1.66 · Cited by 385
A randomized controlled trial of prednisone in Alzheimer’s disease
Koch, H. J., & Szecsey, A. (2000) · Neurology · doi:10.1212/wnl.55.7.1067 · Cited by 384 · cited 1×
“Treatment with low dose prednisone for 1 year failed to show benefit in patients with mild-to-moderate AD [64].”
BackgroundJin, S.-L. C., & Conti, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122041599 · Cited by 367
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Li, P., Zheng, Y., & Chen, X. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00460 · Cited by 346
Peppel, K., Crawford, D., & Beutler, B. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.6.1483 · Cited by 321 · cited 1×
“Etanercept (Enbrel1) is a fusion of soluble TNF receptor 2 with the Fc portion of mouse immunoglobulin G1 [17].”
BackgroundBemiller, S. M., McCray, T. J., Allan, K., Formica, S. V., Xu, G., Wilson, G., Kokiko-Cochran, O. N., Crish, S. D., Lasagna-Reeves, C. A., Ransohoff, R. M., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0216-6 · Cited by 299
A General Overview of Mantel-Haenszel Methods: Applications and Recent Developments
Kuritz, S. J., Landis, J. R., & Koch, G. G. (1988) · Annual Review of Public Health · doi:10.1146/annurev.pu.09.050188.001011 · Cited by 248 · cited 5×
“To compute the AORs of dementia for the drug use group versus the non-drug use group, or for the inflammatory disease group versus the non-inflammatory disease group, we first calculated the OR for each of the 8 strata (tabulation of 2 age groups: 18–65, and>65 years; 2 genders: male and female; and 2 races: White and…”
MethodInfluentialEtanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
Butchart, J., Brook, L., Hopkins, V., Teeling, J., Püntener, U., Culliford, D., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 248
Qin, B., Yang, M., Fu, H., Ma, N., Wei, T., Tang, Q., Hu, Z., Liang, Y., Yang, Z., & Zhong, R. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0601-x · Cited by 239
Development of the Logical Observation Identifier Names and Codes (LOINC) Vocabulary
Huff, S. M., Rocha, R. A., McDonald, C. J., De Moor, G. J. E., Fiers, T., Bidgood, W. D., Forrey, A. W., Francis, W. G., Tracy, W. R., Leavelle, D., et al. (1998) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.1998.0050276 · Cited by 235 · cited 1×
“Specifically, systematized nomenclature of medicine– clinical terms (SNOMED-CT) are used to map disease diagnoses, clinical findings, procedures, and pharmacological drug classes [22]; individual drug names are mapped into RxNorm [23], and lab results and measurements are mapped into logical observation identifiers na…”
MethodJespers, L. S., Roberts, A., Mahler, S. M., Winter, G., & Hoogenboom, H. R. (1994) · Nature Biotechnology · doi:10.1038/nbt0994-899 · Cited by 233 · cited 1×
“Adalimumab (Humira1) is a fully human, anti-TNF monoclonal antibody [18], while infliximab (Remicade1) is a chimeric mouse-human monoclonal antibody in which the antigen combining region of a mouse anti-TNF monoclonal antibody is fused to a human Fc domain [19].”
BackgroundTNFα Transport across the Blood–Brain Barrier Is Abolished in Receptor Knockout Mice
Pan, W., & Kastin, A. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7871 · Cited by 210
The Unified Medical Language System (UMLS) of the National Library of Medicine.
Lindberg, C. H. (1990) · PubMed · Cited by 207
Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis
Chou, R. C., Kane, M., Ghimire, S., Gautam, S., & Gui, J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0374-z · Cited by 194
TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice
Jiang, T., Zhang, Y.-D., Chen, Q., Gao, Q., Zhu, X.-C., Zhou, J.-S., Shi, J.-Q., Lu, H., Tan, L., & Yu, J.-T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.028 · Cited by 176 · cited 1×
“Rare TREM2 mutations associated with AD suggest that TREM2 deficiency contributes to AD risk [52, 53].”
BackgroundFemale sex, early-onset hypertension, and risk of dementia
Gilsanz, P., Mayeda, E. R., Glymour, M. M., Quesenberry, C. P., Mungas, D. M., DeCarli, C., Dean, A., & Whitmer, R. A. (2017) · Neurology · doi:10.1212/wnl.0000000000004602 · Cited by 171
Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases
Willrich, M. A. V., Murray, D. L., & Snyder, M. R. (2014) · Translational research · doi:10.1016/j.trsl.2014.09.006 · Cited by 148 · cited 4×
“NSAIDs are one of three categories of therapeutics used to treat rheumatoid arthritis.[5] The other categories are corticosteroids and disease-modifying antirheumatic drugs (DMARDs).”
BackgroundInfluentialTargeting TNF: a therapeutic strategy for Alzheimer's disease
Cheng, X., Shen, Y., & Li, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.029 · Cited by 135
Alcohol Consumption and Risk of Incident Rheumatoid Arthritis in Women: A Prospective Study
Lü, B., Solomon, D. H., Costenbader, K. H., & Karlson, E. W. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38634 · Cited by 123
Kaelber, D. C., Foster, W., Gilder, J., Love, T. E., & Jain, A. K. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000782 · Cited by 122
Self-citationPhosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121 · cited 2×
“Nominated targets with supporting evidence include multiple elements of the TNF signaling pathway such as TLR4, NFKBIA, NFKBIZ, TNFSR1A [45].”
BackgroundSelf-citationLong term alcohol intake and risk of rheumatoid arthritis in women: a population based cohort study
Giuseppe, D. D., Alfredsson, L. S., Bottai, M., Askling, J., & Wolk, A. (2012) · BMJ · doi:10.1136/bmj.e4230 · Cited by 120
INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
Meyer, P.-F., Tremblay-Mercier, J., Leoutsakos, J., Madjar, C., Lafaille-Maignan, M.-É., Savard, M., Rosa-Neto, P., Poirier, J., Etienne, P., Breitner, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007232 · Cited by 113
Leoutsakos, J. S., Muthen, B. O., Breitner, J. C. S., & Lyketsos, C. G. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2723 · Cited by 104
Ghosh, M., Garcia‐Castillo, D., Aguirre, V., Golshani, R., Atkins, C. M., Bramlett, H. M., Dietrich, W. D., & Pearse, D. D. (2012) · Glia · doi:10.1002/glia.22401 · Cited by 97 · cited 2×
“For example, this pathway is modulated in monocytes, macrophages and microglia by phosphodiesterase-4B (PDE4B) [56, 57], while treatment with a PDE4B allosteric inhibitor after acute brain injury reduces microglial activation, reduces production of TNF, and provides neuroprotective benefit in rats [58].”
BackgroundThe impact of alcohol on Alzheimer's disease: A systematic review
Piazza-Gardner, A. K., Gaffud, T. J. B., & Barry, A. E. (2013) · Aging & Mental Health · doi:10.1080/13607863.2012.742488 · Cited by 94
Favalli, E. G., Pregnolato, F., Biggioggero, M., Becciolini, A., Penatti, A. E., Marchesoni, A., & Meroni, P. L. (2015) · Arthritis Care & Research · doi:10.1002/acr.22788 · Cited by 92 · cited 3×
“The average treatment retention time varies among the three TNF blocking agents selected for study with etanercept having a better than 50% patient retention rate at 12 years of treatment, while the 50% retention rates for adalimumab and infliximab are about 2 and 3 years, respectively [39, 40].”
BackgroundTLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease
Chakrabarty, P., Li, A., Ladd, T. B., Strickland, M. R., Koller, E. J., Burgess, J. D., Funk, C. C., Cruz, P. E., Allen, M., Yaroshenko, M., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180484 · Cited by 78 · cited 1×
“Alzheimer’s brain and soluble fragments have been shown to act as decoy receptors to ameliorate disease phenotypes in a transgenic mouse model of AD [46].”
BackgroundPage, T. H., Turner, J. J. O., Brown, A. C., Timms, E. M., Inglis, J. J., Brennan, F. M., Foxwell, B. M. J., Ray, K. P., & Feldmann, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000906 · Cited by 77 · cited 1×
“NSAIDs suppress prostaglandin synthesis by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, and thereby reduce immune cell activation, but may increase TNF production [55, 63].”
BackgroundWinhusen, T., Theobald, J., Kaelber, D. C., & Lewis, D. (2019) · Addiction · doi:10.1111/add.14607 · Cited by 77
Self-citationThe Need for a Global Language - SNOMED CT Introduction.
Millar, J. (2016) · PubMed · Cited by 62
TREM2 Attenuates Aβ1-42-Mediated Neuroinflammation in BV-2 Cells by Downregulating TLR Signaling
Long, H., Zhong, G., Wang, C., Zhang, J., Zhang, Y., Luo, J., & Shi, S. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02817-1 · Cited by 59
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
Tansey, M., & McAlpine (2008) · Journal of Inflammation Research · doi:10.2147/jir.s4397 · Cited by 54 · cited 1×
“TNF signaling can be targeted by small molecule therapeutics [7, 9, 55].”
BackgroundTherapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury
Wilson, N. M., Gurney, M. E., Dietrich, W. D., & Atkins, C. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178013 · Cited by 42 · cited 1×
“For example, this pathway is modulated in monocytes, macrophages and microglia by phosphodiesterase-4B (PDE4B) [56, 57], while treatment with a PDE4B allosteric inhibitor after acute brain injury reduces microglial activation, reduces production of TNF, and provides neuroprotective benefit in rats [58].”
BackgroundSelf-citationPapadopoulos, C. G., Gartzonikas, I. K., Pappa, T. K., Markatseli, T. E., Migkos, M. P., Voulgari, P. V., & Drosos, A. A. (2019) · Rheumatology Advances in Practice · doi:10.1093/rap/rkz007 · Cited by 28
Patel, V. N., & Kaelber, D. C. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2013.10.009 · Cited by 25
Self-citationGorenjak, V., Arguinano, A.-A. A., Dadé, S., Stathopoulou, M. G., Vance, D. R., Masson, C., & Visvikis‐Siest, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-25553-y · Cited by 5
Cited by
Wang, Q. Q., Kaelber, D. C., Xu, R., & Volkow, N. D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00880-7 · Cited by 634
Self-citationWang, Q., Xu, R., & Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20806 · Cited by 617
Self-citationNeuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics
Thakur, S., Dhapola, R., Sarma, P., Medhi, B., & Reddy, D. H. (2023) · Inflammation · doi:10.1007/s10753-022-01721-1 · Cited by 557
Wang, Q., Berger, N. A., & Xu, R. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6178 · Cited by 390
Self-citationNeuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
“Indeed, patients with rheumatic disorders that are treated with TNF-blocking agents have a lower risk for developing AD [353].”
Background
Metadata
- Authors
- Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E.
- Affiliations
- Case Western Reserve University (US)
- MetroHealth (US)
- Tetra Therapeutics (United States) (US)
- Corresponding author
- Xu, Rong
- Gurney, Mark E.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-03-23
- Volume
- 15
- Issue
- 3
- Pages
- e0229819
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7089534
- OpenAlex
- W3012855465
- Cited by
- 157
- References
- 66
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 23 · 2023: 27 · 2022: 38 · 2021: 21 · 2020: 13
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (DP2HD084068)
- National Institute on Aging (R01 AG057557, R01 AG061388, R56 AG062272)
- American Cancer Society (RSG-16-049-01 - MPC)
- National Institute of Mental Health (MH091791, MH107077)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, TNF-alpha inhibitors, rheumatoid arthritis, psoriasis, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, etanercept, adalimumab, infliximab, methotrexate, anti-TNF therapy, neurodegeneration risk, electronic health records, pharmacoepidemiology
- MeSH terms
- Etanercept, Adalimumab, Infliximab, Tumor Necrosis Factor Inhibitors, Adolescent, Adult, Aged, Alzheimer Disease, Arthritis, Rheumatoid, Colitis, Ulcerative, Female, Humans, Male, Methotrexate, Middle Aged, Retrospective Studies, Risk, Arthritis, Psoriatic, Case-Control Studies, Antirheumatic Agents, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.